1
|
Gottschlich A, Grünmeier R, Hoffmann GV, Nandi S, Kavaka V, Müller PJ, Jobst J, Oner A, Kaiser R, Gärtig J, Piseddu I, Frenz-Wiessner S, Fairley SD, Schulz H, Igl V, Janert TA, Di Fina L, Mulkers M, Thomas M, Briukhovetska D, Simnica D, Carlini E, Tsiverioti CA, Trefny MP, Lorenzini T, Märkl F, Mesquita P, Brabenec R, Strzalkowski T, Stock S, Michaelides S, Hellmuth J, Thelen M, Reinke S, Klapper W, Gelebart PF, Nicolai L, Marr C, Beltrán E, Megens RTA, Klein C, Baran-Marszak F, Rosenwald A, von Bergwelt-Baildon M, Bröckelmann PJ, Endres S, Kobold S. Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma. Blood 2025; 145:1536-1552. [PMID: 40178843 PMCID: PMC12002222 DOI: 10.1182/blood.2023022197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2023] [Accepted: 11/11/2024] [Indexed: 04/05/2025] Open
Abstract
ABSTRACT The success of targeted therapies for hematological malignancies has heralded their potential as both salvage treatment and early treatment lines, reducing the need for high-dose, intensive, and often toxic chemotherapeutic regimens. For young patients with classic Hodgkin lymphoma (cHL), immunotherapies provide the possibility to lessen long-term, treatment-related toxicities. However, suitable therapeutic targets are lacking. By integrating single-cell dissection of the tumor landscape and an in-depth, single-cell-based off-tumor antigen prediction, we identify CD86 as a promising therapeutic target in cHL. CD86 is highly expressed on Hodgkin and Reed-Sternberg cancer cells and cHL-specific tumor-associated macrophages. We reveal CD86-CTLA-4 as a key suppressive pathway in cHL, driving T-cell exhaustion. Cellular therapies targeting CD86 had extraordinary efficacy in vitro and in vivo and were safe in immunocompetent mouse models without compromising bacterial host defense in sepsis models. Our results prove the potential value of anti-CD86 immunotherapies for treating cHL.
Collapse
Affiliation(s)
- Adrian Gottschlich
- Department of Medicine III, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Munich, Germany
- Division of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany
- Bavarian Cancer Research Center, Munich, Germany
- German Cancer Consortium, a partnership between Ludwig Maximilian University Hospital and German Cancer Consortium Heidelberg, Munich, Germany
| | - Ruth Grünmeier
- Division of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany
| | - Gordon Victor Hoffmann
- Division of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany
| | - Sayantan Nandi
- Division of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany
| | - Vladyslav Kavaka
- Department of Hand, Plastic, Reconstructive and Burn Surgery, BG Unfallklinik Tuebingen, Eberhard Karls University Tuebingen, Tuebingen, Germany
- Institute of Clinical Neuroimmunology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Munich, Germany
- Biomedical Center, Faculty of Medicine, Ludwig Maximilian University Munich, Martinsried, Germany
| | - Philipp Jie Müller
- Division of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany
| | - Jakob Jobst
- Division of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany
| | - Arman Oner
- Division of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany
| | - Rainer Kaiser
- Department of Medicine I, LMU University Hospital, LMU Munich, Munich, Germany
- German Center for Cardiovascular Research, Partner Site Munich Heart Alliance, Munich, Germany
| | - Jan Gärtig
- Division of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany
| | - Ignazio Piseddu
- Division of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany
- Bavarian Cancer Research Center, Munich, Germany
- Department of Medicine II, LMU University Hospital, LMU Munich, Munich, Germany
| | - Stephanie Frenz-Wiessner
- Department of Pediatrics, Dr. von Hauner Children's Hospital, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Munich, Germany
- German Center for Child and Adolescent Health, Partner Site Munich, Munich, Germany
| | - Savannah D. Fairley
- Department of Pediatrics, Dr. von Hauner Children's Hospital, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Munich, Germany
- Institute of Cardiovascular Prevention, LMU Munich, Munich, Germany
| | - Heiko Schulz
- Institute of Pathology, Faculty of Medicine, Ludwig Maximilian University Munich, Munich, Germany
| | - Veronika Igl
- Division of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany
| | - Thomas Alexander Janert
- Division of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany
| | - Lea Di Fina
- Department of Medicine I, LMU University Hospital, LMU Munich, Munich, Germany
| | - Maité Mulkers
- Department of Medicine I, LMU University Hospital, LMU Munich, Munich, Germany
| | - Moritz Thomas
- Institute of AI for Health, Helmholtz Zentrum München-German Research Center for Environmental Health Neuherberg, Neuherberg, Germany
- School of Life Sciences Weihenstephan, Technical University of Munich, Freising, Germany
| | - Daria Briukhovetska
- Division of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany
| | - Donjetë Simnica
- Division of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany
| | - Emanuele Carlini
- Division of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany
| | - Christina Angeliki Tsiverioti
- Division of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany
| | - Marcel P. Trefny
- Division of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany
| | - Theo Lorenzini
- Division of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany
| | - Florian Märkl
- Division of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany
| | - Pedro Mesquita
- Division of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany
| | - Ruben Brabenec
- Division of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany
- Institute of AI for Health, Helmholtz Zentrum München-German Research Center for Environmental Health Neuherberg, Neuherberg, Germany
| | - Thaddäus Strzalkowski
- Division of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany
| | - Sophia Stock
- Department of Medicine III, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Munich, Germany
- Division of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany
- German Cancer Consortium, a partnership between Ludwig Maximilian University Hospital and German Cancer Consortium Heidelberg, Munich, Germany
| | - Stefanos Michaelides
- Division of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany
| | - Johannes Hellmuth
- Department of Medicine III, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Munich, Germany
| | - Martin Thelen
- Department of General, Visceral, Thoracic, and Transplantation Surgery
- Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
| | - Sarah Reinke
- Hematopathology Section, Department of Pathology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - Wolfram Klapper
- Hematopathology Section, Department of Pathology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - Pascal Francois Gelebart
- Department of Clinical Science, University of Bergen, Bergen, Norway
- Department of Hematology, Haukeland University Hospital, Bergen, Norway
| | - Leo Nicolai
- Department of Medicine I, LMU University Hospital, LMU Munich, Munich, Germany
- German Center for Cardiovascular Research, Partner Site Munich Heart Alliance, Munich, Germany
| | - Carsten Marr
- Institute of AI for Health, Helmholtz Zentrum München-German Research Center for Environmental Health Neuherberg, Neuherberg, Germany
| | - Eduardo Beltrán
- Institute of Clinical Neuroimmunology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Munich, Germany
- Biomedical Center, Faculty of Medicine, Ludwig Maximilian University Munich, Martinsried, Germany
- Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
| | - Remco T. A. Megens
- Institute of Cardiovascular Prevention, LMU Munich, Munich, Germany
- Department of Biomedical Engineering, Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maastricht, The Netherlands
- German Center for Cardiovascular Research, Partner Site Munich Heart Alliance, Munich, Germany
| | - Christoph Klein
- Department of Pediatrics, Dr. von Hauner Children's Hospital, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Munich, Germany
- German Center for Child and Adolescent Health, Partner Site Munich, Munich, Germany
- Gene Center, Ludwig Maximilian University Munich, Munich, Germany
| | - Fanny Baran-Marszak
- INSERM U978, University of Paris 13, Bobigny, France
- Service d’Hématologie Biologique, Hôpitaux Universitaire Paris Seine Saint Denis, Hôpital Avicenne, Université Sorbonne Paris Nord Bobigny, Paris, France
| | - Andreas Rosenwald
- Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany
- Institute of Pathology, University of Würzburg, Würzburg, Germany
| | - Michael von Bergwelt-Baildon
- Department of Medicine III, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Munich, Germany
- Bavarian Cancer Research Center, Munich, Germany
- German Cancer Consortium, a partnership between Ludwig Maximilian University Hospital and German Cancer Consortium Heidelberg, Munich, Germany
| | - Paul J. Bröckelmann
- Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf and German Hodgkin Study Group, Cologne, Germany
- Max Planck Institute for Biology of Ageing, Cologne, Germany
| | - Stefan Endres
- Division of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany
- German Cancer Consortium, a partnership between Ludwig Maximilian University Hospital and German Cancer Consortium Heidelberg, Munich, Germany
- Einheit für Klinische Pharmakologie, Helmholtz Zentrum München-German Research Center for Environmental Health Neuherberg, Neuherberg, Germany
| | - Sebastian Kobold
- Division of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany
- German Cancer Consortium, a partnership between Ludwig Maximilian University Hospital and German Cancer Consortium Heidelberg, Munich, Germany
- Einheit für Klinische Pharmakologie, Helmholtz Zentrum München-German Research Center for Environmental Health Neuherberg, Neuherberg, Germany
| |
Collapse
|
2
|
Kalra SK, Sancheti S, Somal PK, Sali AP, Sharma A, Goel A, Jain S, Dora TK, Gulia A, Divetia JV. Challenges Encountered and Pattern-Based Analysis of Bone Marrow Biopsy in Lymphomas: An Institutional Experience. J Lab Physicians 2022; 15:69-77. [PMID: 37064982 PMCID: PMC10104704 DOI: 10.1055/s-0042-1751318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022] Open
Abstract
Abstract
Objective The evaluation of bone marrow (BM) status is an integral part of the initial workup of patients diagnosed with lymphoma as it plays an important role in staging and predicting prognosis in these patients. This article determines the incidence and pattern of BM involvement in lymphoma cases and distinguishes benign from malignant lymphoid aggregates in BM biopsies.
Materials and Methods The study group included 121 cases of Hodgkin and non-Hodgkin lymphomas for which BM biopsies were performed, fixed in acetic acid-zinc formalin solution, decalcified using 10% formic acid, and subjected to hematoxylin and eosin and immunohistochemistry.
Results The overall incidence of BM biopsy involvement in our study was 31.4% (37/118), including 34.7% (35/101) in cases of B cell lymphomas, 25% (2/8) in cases of T cell lymphomas, and no involvement in Hodgkin lymphoma. The predominant histological pattern of BM involvement was diffused (14/37; 37.8%), followed by interstitial (10/37; 27.1%). Five cases revealed benign nonparatrabecular lymphoid aggregates which could be confused with lymphomatous involvement, especially in low grade lymphomas.
Conclusion A careful examination of the BM biopsies along with clinical history, peripheral blood examination, flow cytometry, and immunohistochemistry will help in arriving at the correct diagnosis.
Collapse
Affiliation(s)
- Supreet Kaur Kalra
- Department of Pathology, Homi Bhabha Cancer Hospital and Research Centre (a unit of Tata Memorial Centre), Sangrur, Punjab, India
| | - Sankalp Sancheti
- Department of Pathology, Homi Bhabha Cancer Hospital and Research Centre (a unit of Tata Memorial Centre), Sangrur, Punjab, India
| | - Puneet Kaur Somal
- Department of Pathology, Homi Bhabha Cancer Hospital and Research Centre (a unit of Tata Memorial Centre), Sangrur, Punjab, India
| | - Akash Pramod Sali
- Department of Pathology, Homi Bhabha Cancer Hospital and Research Centre (a unit of Tata Memorial Centre), Sangrur, Punjab, India
| | - Aishwarya Sharma
- Department of Pathology, Homi Bhabha Cancer Hospital and Research Centre (a unit of Tata Memorial Centre), Sangrur, Punjab, India
| | - Alok Goel
- Department of Medical Oncology, Homi Bhabha Cancer Hospital and Research Centre (a unit of Tata Memorial Centre), Sangrur, Punjab, India
| | - Shivani Jain
- Department of Medical Oncology, Homi Bhabha Cancer Hospital and Research Centre (a unit of Tata Memorial Centre), Sangrur, Punjab, India
| | - Tapas Kumar Dora
- Department of Radiation Oncology, Homi Bhabha Cancer Hospital and Research Centre (a unit of Tata Memorial Centre), Sangrur, Punjab, India
| | - Ashish Gulia
- Department of Surgical Oncology, Homi Bhabha Cancer Hospital and Research Centre (a unit of Tata Memorial Centre), Sangrur, Punjab, India
| | - Jigeeshu V. Divetia
- Department of Surgical Oncology, Homi Bhabha Cancer Hospital and Research Centre (a unit of Tata Memorial Centre), Sangrur, Punjab, India
- Department of Anaesthesiology, Homi Bhabha Cancer Hospital and Research Centre (a unit of Tata Memorial Centre), Sangrur, Punjab, India
| |
Collapse
|
3
|
Duś-Szachniewicz K, Drobczyński S, Woźniak M, Zduniak K, Ostasiewicz K, Ziółkowski P, Korzeniewska AK, Agrawal AK, Kołodziej P, Walaszek K, Bystydzieński Z, Rymkiewicz G. Differentiation of single lymphoma primary cells and normal B-cells based on their adhesion to mesenchymal stromal cells in optical tweezers. Sci Rep 2019; 9:9885. [PMID: 31285461 PMCID: PMC6614388 DOI: 10.1038/s41598-019-46086-y] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2019] [Accepted: 06/21/2019] [Indexed: 01/01/2023] Open
Abstract
We have adapted a non-invasive method based on optical tweezers technology to differentiate between the normal B-cells and the B-cell non-Hodgkin lymphoma (B-NHL) cells derived from clinical samples. Our approach bases on the nascent adhesion between an individual B-cell and a mesenchymal stromal cell. In this study, a single B-cell was trapped and optically seeded on a mesenchymal stromal cell and kept in a direct contact with it until a stable connection between the cells was formed in time scale. This approach allowed us to avoid the introduction of any exogenous beads or chemicals into the experimental setup which would have affected the cell-to-cell adhesion. Here, we have provided new evidence that aberrant adhesive properties found in transformed B-cells are related to malignant neoplasia. We have demonstrated that the mean time required for establishing adhesive interactions between an individual normal B-cell and a mesenchymal stromal cell was 26.7 ± 16.6 s, while for lymphoma cell it was 208.8 ± 102.3 s, p < 0.001. The contact time for adhesion to occur ranged from 5 to 90 s and from 60 to 480 s for normal B-cells and lymphoma cells, respectively. This method for optically controlled cell-to-cell adhesion in time scale is beneficial to the successful differentiation of pathological cells from normal B-cells within the fine needle aspiration biopsy of a clinical sample. Additionally, variations in time-dependent adhesion among subtypes of B-NHL, established here by the optical trapping, confirm earlier results pertaining to cell heterogeneity.
Collapse
Affiliation(s)
- Kamila Duś-Szachniewicz
- Department of Pathology, Wrocław Medical University, Marcinkowskiego 1, 50-368, Wrocław, Poland.
| | - Sławomir Drobczyński
- Department of Optics and Photonics, Wrocław University of Science and Technology, Faculty of Fundamental Problems of Technology, Wybrzeże Wyspiańskiego 27, 50-370, Wrocław, Poland
| | - Marta Woźniak
- Department of Pathology, Wrocław Medical University, Marcinkowskiego 1, 50-368, Wrocław, Poland
| | - Krzysztof Zduniak
- Department of Pathology, Wrocław Medical University, Marcinkowskiego 1, 50-368, Wrocław, Poland
| | - Katarzyna Ostasiewicz
- Department of Statistics, Wrocław University of Economics, Komandorska 118/120, 53-345, Wrocław, Poland
| | - Piotr Ziółkowski
- Department of Pathology, Wrocław Medical University, Marcinkowskiego 1, 50-368, Wrocław, Poland
| | - Aleksandra K Korzeniewska
- Department of Optics and Photonics, Wrocław University of Science and Technology, Faculty of Fundamental Problems of Technology, Wybrzeże Wyspiańskiego 27, 50-370, Wrocław, Poland
| | - Anil K Agrawal
- 2nd Department of General and Oncological Surgery, Wrocław Medical University, Borowska 213, 50-556, Wrocław, Poland
| | - Paweł Kołodziej
- Division of Pathology, Sokołowski Hospital Wałbrzych, Sokołowskiego 4, 58-309, Wałbrzych, Poland
| | - Kinga Walaszek
- Department of Pathology, Wrocław Medical University, Marcinkowskiego 1, 50-368, Wrocław, Poland
| | - Zbigniew Bystydzieński
- Flow Cytometry Laboratory, Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Institute-Oncology Centre, Wilhelma Konrada Roentgena 5, 02-781, Warsaw, Poland
| | - Grzegorz Rymkiewicz
- Flow Cytometry Laboratory, Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Institute-Oncology Centre, Wilhelma Konrada Roentgena 5, 02-781, Warsaw, Poland
| |
Collapse
|
6
|
Sun Q, An G, Liu E, Li Z, Zhang H, Yang Q, Sun F, Ma Y, Xian M, Zhang P, Ru K. [The clinic and pathologic significance of plasma cell myeloma with CCND1]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2015; 36:775-9. [PMID: 26462780 PMCID: PMC7342711 DOI: 10.3760/cma.j.issn.0253-2727.2015.09.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/09/2015] [Indexed: 11/05/2022]
Abstract
OBJECTIVE To study the clinical and pathologic features of multiple myeloma(MM) with CCND1. METHODS Retrospectively analyzed the clinical and pathologic profiles of 158 patients with MM from 2010 to 2013. The clinical and morphologic features of bone marrow aspiration, biopsy and immunophenotypic analysis which was carried out by flow cytometry and immunohistochemistry were analyzed in all patients with MM respectively. CCND1 translocation was studied by FISH method in all cases. Classical cytogenetic studies of bone marrow were performed in 24 cases whose CCND1 was positive. RESULTS In the 158 patients with MM, CCND1 was detected in 31 patients (19.6%). In 31 patients, type IgA, IgD, IgG, IgM, light-chain only and nonsecretory MM were 4 cases,4 cases,11 cases,1 case, 6 cases and 5 cases respectively. A high incidence of CCND1 was observed in IgD and nonsecretory MM comparied with IgA and IgG respectively (P<0.05). but no statistical significance was reached between κ and λ type patients (P=0.627). The morphology of plasma cell in bone marrow biopsies were small Lymphocyte- Like 24 cases,mature plasma cell 6 cases and immature plasma cell 1 case. Immunophenotype of all 31 cases was CD38⁺CD138⁺CD19⁻CD45⁻, (CD56⁺ in 11 cases, CD20⁺ in 9 cases, CD117⁺ in 3 cases. MM with CCND1 showed a strong association with CD20 expression, the lack of CD56 expression. Immunohistochemistry showed positive for cyclinD1 in 22 cases. CONCLUSION A high incidence of CCND1 was detected in the IgD and nonsecretory MM, and correlated with Small Lymphocyte- Like, higher positive rate of CD20, cyclinD1 and the lack of CD56 expression. MM with CCND1 must be distinguished from LPL and other mature B cell lymphomas which have plasmacytoid differentiation.
Collapse
Affiliation(s)
- Qi Sun
- Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | - Gang An
- Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | - Enbin Liu
- Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | - Zhanqi Li
- Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | - Hongju Zhang
- Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | - Qingying Yang
- Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | - Fujun Sun
- Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | - Yue Ma
- Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | - Mu Xian
- Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | - Peihong Zhang
- Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | - Kun Ru
- Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| |
Collapse
|